Market Price

52.60 

-0.50 -0.9%

as of Jan 22 '21

52 Week Range:

39.00 85.70


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 23.43
20.00
10.42
6.38
4.91
growth rate -14.6% -47.9% -38.8% -23.0%
Earnings BIT -96.94
-89.26
-399.42
-87.58
-97.37
-45.98
-112.80
96.10
36.80
89.50
229.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -61.7% 143.2% 155.9%
Avg.PE -9.10
-10.60
-2.50
-12.40
-4.70
-4.70
-4.70
39.40
59.10
18.45
9.69
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 50.0% -68.8% -47.5%
ROA -14.50
-13.10
-62.30
-16.70
-24.70
growth rate 0.0% 0.0% 0.0% 0.0%
ROE -17.50
-17.60
-100.60
-34.20
-87.90
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 60.70
119.80
77.00
32.00
49.64
169.68
202.90
195.10
245.20
281.60
261.10
growth rate 97.4% -35.7% -58.4% 55.1% 241.8% 19.6% -3.8% 25.7% 14.9% -7.3%
Acct.Payable 27.00
20.00
138.01
28.88
34.90
36.00
45.50
47.70
49.40
growth rate -25.9% 590.0% -79.1% 20.8% 3.2% 26.4% 4.8% 3.6%
Cur.Assets 156.50
263.60
356.00
293.00
544.30
936.42
819.70
825.80
827.40
1,059.50
1,221.20
growth rate 68.4% 35.1% -17.7% 85.8% 72.0% -12.5% 0.7% 0.2% 28.1% 15.3%
Total Assets 649.30
712.70
546.00
482.00
772.33
1,225.89
1,020.00
1,018.80
1,003.90
1,286.70
1,501.10
growth rate 9.8% -23.4% -11.7% 60.2% 58.7% -16.8% -0.1% -1.5% 28.2% 16.7%
Cash 87.40
135.80
247.00
228.00
105.64
284.48
198.10
282.40
327.90
589.80
816.80
growth rate 55.4% 81.9% -7.7% -53.7% 169.3% -30.4% 42.6% 16.1% 79.9% 38.5%
Inventory 8.40
8.00
27.00
28.00
383.41
478.14
402.60
344.20
250.20
173.60
131.80
growth rate -4.8% 237.5% 3.7% 1,269.3% 24.7% -15.8% -14.5% -27.3% -30.6% -24.1%
Cur.Liabilities 67.00
140.00
118.00
169.00
497.15
268.10
248.80
309.50
349.90
483.40
461.00
growth rate 109.0% -15.7% 43.2% 194.2% -46.1% -7.2% 24.4% 13.1% 38.2% -4.6%
Liabilities 100.70
244.50
235.00
291.00
610.87
770.86
749.90
708.50
674.80
810.60
794.70
growth rate 142.8% -3.9% 23.8% 109.9% 26.2% -2.7% -5.5% -4.8% 20.1% -2.0%
LT Debt 12.80
94.40
115.00
114.00
104.08
493.76
494.40
397.80
319.10
320.60
289.60
growth rate 637.5% 21.8% -0.9% -8.7% 374.4% 0.1% -19.5% -19.8% 0.5% -9.7%
Equity 548.70
468.20
311.10
191.20
161.50
455.02
270.10
310.30
329.10
476.10
706.40
growth rate -14.7% -33.6% -38.5% -15.5% 181.8% -40.6% 14.9% 6.1% 44.7% 48.4%
Common Shares 23.41
23.42
29.87
29.95
1,492.63
13.74
13.80
13.90
14.10
14.20
14.20
growth rate 0.0% 27.5% 0.3% 4,883.7% -99.1% 0.5% 0.7% 1.4% 0.7% 0.0%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 2.60
3.40
5.00
6.00
107.51
71.72
0.30
1.10
1.10
2.90
5.00
growth rate 30.8% 47.1% 20.0% 1,691.8% -33.3% -99.6% 266.7% 0.0% 163.6% 72.4%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -133.93
-42.97
-117.23
29.00
-263.20
-487.30
-109.20
156.20
146.60
242.00
287.00
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -6.2% 65.1% 18.6%
Sale Purchase of Stock 349.32
3.80
2.30
0.10
growth rate -98.9% -39.5% -95.7%
FCF -136.50
-46.40
-122.00
22.90
-370.71
-559.02
-109.50
155.10
145.50
239.10
282.00
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -6.2% 64.3% 17.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 236.10
210.50
200.00
326.00
429.36
570.32
646.20
705.90
643.70
783.10
844.80
growth rate -10.8% -5.0% 63.0% 31.7% 32.8% 13.3% 9.2% -8.8% 21.7% 7.9%
Op.Income -99.10
-81.80
-392.00
-86.00
-97.37
-45.98
-112.80
96.10
36.80
89.50
229.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -61.7% 143.2% 155.9%
IBT -96.90
-89.30
-399.40
-87.60
-153.40
-52.55
-203.60
35.50
29.70
92.20
227.90
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -16.3% 210.4% 147.2%
Net Income -98.10
-89.20
-392.00
-86.00
-154.94
-56.58
-210.00
29.00
23.20
137.90
219.10
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -20.0% 494.4% 58.9%
EPS -4.32
-3.81
-14.43
-2.92
-5.16
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 212.50
184.20
171.00
298.00
400.01
462.87
496.00
556.30
479.30
611.30
739.20
growth rate -13.3% -7.2% 74.3% 34.2% 15.7% 7.2% 12.2% -13.8% 27.5% 20.9%
R&D 222.30
161.10
194.40
216.20
238.10
197.82
172.60
132.30
134.20
166.80
181.30
growth rate -27.5% 20.7% 11.2% 10.1% -16.9% -12.8% -23.4% 1.4% 24.3% 8.7%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT 97.60
32.70
23.90
-6.10
-24.20
growth rate -66.5% -26.9% -100.0% 0.0%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 286.40
261.10
241.60
253.60
213.20
growth rate -8.8% -7.5% 5.0% -15.9%
Acct.Payable 49.40
growth rate
Cur.Assets 1,236.40
1,221.20
1,243.00
1,057.00
927.20
growth rate -1.2% 1.8% -15.0% -12.3%
Total Assets 1,545.30
1,501.10
1,550.40
1,463.00
1,328.20
growth rate -2.9% 3.3% -5.6% -9.2%
Cash 812.90
816.80
861.40
677.20
593.30
growth rate 0.5% 5.5% -21.4% -12.4%
Inventory 137.00
131.80
140.10
126.20
120.70
growth rate -3.8% 6.3% -9.9% -4.4%
Cur.Liabilities 537.90
461.00
461.60
444.50
407.00
growth rate -14.3% 0.1% -3.7% -8.4%
Liabilities 873.60
794.70
775.10
727.50
708.80
growth rate -9.0% -2.5% -6.1% -2.6%
LT Debt 289.20
289.60
249.50
223.80
224.10
growth rate 0.1% -13.9% -10.3% 0.1%
Equity 671.70
706.40
775.30
735.50
619.40
growth rate 5.2% 9.8% -5.1% -15.8%
Common Shares 671.70
14.20
775.30
735.50
619.40
growth rate -97.9% 5,359.9% -5.1% -15.8%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 13.70
-9.50
3.90
106.60
50.20
growth rate -100.0% 100.0% 2,633.3% -52.9%
Cash Dividends
growth rate
Cash From OA 135.70
56.30
48.10
-7.20
-12.90
growth rate -58.5% -14.6% -100.0% 0.0%
Sale Purchase of Stock
growth rate
FCF 122.00
46.80
44.20
-113.80
-63.10
growth rate -61.6% -5.6% -100.0% 0.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 231.20
238.10
175.00
179.10
150.30
growth rate 3.0% -26.5% 2.3% -16.1%
Op.Income 97.60
32.70
23.90
-6.10
-24.20
growth rate -66.5% -26.9% -100.0% 0.0%
IBT 114.70
48.90
78.00
-35.50
-40.50
growth rate -57.4% 59.5% -100.0% 0.0%
Net Income 111.70
38.80
82.60
-32.50
-84.90
growth rate -65.3% 112.9% -100.0% 0.0%
EPS
growth rate
Gross Profit 205.30
215.00
155.00
159.20
135.80
growth rate 4.7% -27.9% 2.7% -14.7%
R&D 41.60
58.60
52.90
62.60
50.30
growth rate 40.9% -9.7% 18.3% -19.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (59.75)

YOY Growth Grade:

E (20.65)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 457.39 457.39 11.05
EPS / Growth 0.0% 0.12 339.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 22.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 11.5% 11.5%
Future PE 0.00 16.99 16.99
Future EPS 0.12 0.34 0.34
Value Price
MOS %
0.00
-100.0%
1.43
-97.3%
1.43
-97.3%
MOS Price 0.00 0.71 0.71
IRT 99.00 35.67 35.67

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.